Fayez Sarofim & CO Biogen Inc. Transaction History

Fayez Sarofim & CO

$38.7 Billion
Q3 2024

A detailed history of Fayez Sarofim & CO transactions in Biogen Inc. stock. As of the latest transaction made, Fayez Sarofim & CO holds 2,300 shares of BIIB stock, worth $331,039. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,300

Previous 2,300 -0.0%

Holding current value

$331,039

Previous $533,000 16.51%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$275.25 - $318.06 $1.41 Million - $1.63 Million	-5,113 Reduced 68.97%	2,300 $655,000
Q2 2022 Aug 12, 2022	SELL	$187.54 - $223.02 $59,075 - $70,251	-315 Reduced 4.08%	7,413 $1.51 Million
Q1 2022 May 16, 2022	SELL	$193.77 - $244.14 $445,671 - $561,522	-2,300 Reduced 22.94%	7,728 $1.63 Million
Q1 2021 May 13, 2021	SELL	$242.95 - $284.63 $369,284 - $432,637	-1,520 Reduced 13.16%	10,028 $2.81 Million
Q3 2020 Nov 13, 2020	BUY	$264.77 - $305.71 $389,211 - $449,393	1,470 Added 14.59%	11,548 $3.28 Million
Q2 2020 Aug 11, 2020	BUY	$258.66 - $342.55 $7,759 - $10,276	30 Added 0.3%	10,078 $2.7 Million
Q4 2019 Feb 14, 2020	BUY	$220.06 - $304.07 $69,318 - $95,782	315 Added 3.24%	10,048 $2.98 Million
Q2 2019 Aug 09, 2019	SELL	$219.29 - $241.72 $1.46 Million - $1.61 Million	-6,668 Reduced 40.66%	9,733 $2.28 Million
Q1 2019 May 14, 2019	BUY	$216.71 - $338.96 $1.45 Million - $2.26 Million	6,668 Added 68.51%	16,401 $3.88 Million
Q1 2018 May 10, 2018	BUY	$260.13 - $367.91 $5,202 - $7,358	20 Added 0.21%	9,733 $2.67 Million
Q3 2017 Nov 08, 2017	BUY	$281.15 - $329.69 $2.73 Million - $3.2 Million	9,713	9,713 $3.04 Million

Others Institutions Holding BIIB

# of Institutions

998

Shares Held

130M

Call Options Held

1.12M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $20.7B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fayez Sarofim & CO, based on Form 13F filings with the SEC.

News

Stay updated on Fayez Sarofim & CO with notifications on news.

Account